コンテンツへスキップ
About Us
Message from CEO
Our Mission
Company Profile
Management Team
History
Clinical Development
Ongoing Clinical Studies
MN-166 (Ibudilast)
About MN-166 (Ibudilast)
ALS
Oncology / Glioblastoma
DCM
CIPN
ARDS / Lung Injury
MN-001 (Tipelukast)
About MN-001（Tipelukast)
NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Investor Relations
Press Release
Event
Media Archive
Annual Report
SEC filing
Stock Quote -TSE
Stock Quote -Nasdaq
Historical Price Lookup
Investment Calculator
Analyst Coverage
Corporate Governance
Information Request
Presentation
Corporate Presentation & Resarch Reports
MN-166 Presentation
Progressive Multiple Sclerosis (Progressive MS)
Amyotrophic Lateral Sclerosis (ALS)
Oncology / Glioblastoma
Substance Dependence and Addiction
MN-166 (ibudilast) News Articles
MN-166 (ibudilast) Publications
MN-001 Presentation
Contact Us
Contact Us
Japanese site
About Us
Message from CEO
Our Mission
Company Profile
Management Team
History
Clinical Development
Ongoing Clinical Trial
MN-166 (Ibudilast)
About MN-166 (Ibudilast)
ALS
Oncology / Glioblastoma
DCM
CIPN
ARDS / Lung Injury
MN-001 ( tipelukast)
About MN-001（Tipelukast)
NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Investor Relations
News
Events
Presentations
Stock Quote & Chart
TSE Stock Quote
Analyst Coverage
Equity Research
SEC Filings
Annual Reports
Documents & Charters
Email Alerts
Presentation
Corporate Presentation and Equity Research Analyst Reports
MN-166 Presentation
Progressive Multiple Sclerosis (Progressive MS)
Amyotrophic Lateral Sclerosis (ALS)
Oncology / Glioblastoma
Substance Dependence and Addiction
MN-166 (ibudilast) News Articles
MN-166 (ibudilast) Publications
MN-001 Presentation
Contact Us
従業員株式購入プランの実施(新株発行)に関するお知らせ
2014.10.01
2017.11.22
MN-166のALS（筋萎縮性側索硬化症）を適応とするフェーズ2a臨床治験の詳細に関する学会発表のお知らせ
MN-001 の進行型NASH を適応とする試験結果について、第65 回アメリカ肝臓病学会レイトブレイキングセッションにおける発表への採択のお知らせ
メニュー
About Us
Message from CEO
Our Mission
Company Profile
Management Team
History
Clinical Development
Ongoing Clinical Trial
MN-166 (Ibudilast)
About MN-166 (Ibudilast)
ALS
Oncology / Glioblastoma
DCM
CIPN
ARDS / Lung Injury
MN-001 ( tipelukast)
About MN-001（Tipelukast)
NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Investor Relations
News
Events
Presentations
Stock Quote & Chart
TSE Stock Quote
Analyst Coverage
Equity Research
SEC Filings
Annual Reports
Documents & Charters
Email Alerts
Presentation
Corporate Presentation and Equity Research Analyst Reports
MN-166 Presentation
Progressive Multiple Sclerosis (Progressive MS)
Amyotrophic Lateral Sclerosis (ALS)
Oncology / Glioblastoma
Substance Dependence and Addiction
MN-166 (ibudilast) News Articles
MN-166 (ibudilast) Publications
MN-001 Presentation
Contact Us
検索
